JP2023518396A5 - - Google Patents
Info
- Publication number
- JP2023518396A5 JP2023518396A5 JP2022555911A JP2022555911A JP2023518396A5 JP 2023518396 A5 JP2023518396 A5 JP 2023518396A5 JP 2022555911 A JP2022555911 A JP 2022555911A JP 2022555911 A JP2022555911 A JP 2022555911A JP 2023518396 A5 JP2023518396 A5 JP 2023518396A5
- Authority
- JP
- Japan
- Prior art keywords
- carm1
- gene
- effector
- protein
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991479P | 2020-03-18 | 2020-03-18 | |
| US62/991,479 | 2020-03-18 | ||
| PCT/US2021/023023 WO2021188828A1 (en) | 2020-03-18 | 2021-03-18 | Methods for treating cancer by inhibiting carm1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023518396A JP2023518396A (ja) | 2023-05-01 |
| JP2023518396A5 true JP2023518396A5 (https=) | 2024-03-26 |
Family
ID=77771409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022555911A Pending JP2023518396A (ja) | 2020-03-18 | 2021-03-18 | Ｃａｒｍ１の阻害によるがん治療法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230201166A1 (https=) |
| EP (1) | EP4121070A4 (https=) |
| JP (1) | JP2023518396A (https=) |
| CN (1) | CN115697356A (https=) |
| WO (1) | WO2021188828A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113373170A (zh) * | 2021-04-29 | 2021-09-10 | 江西农业大学 | 一种pFnCpfAb/pCrAb双质粒系统及其应用 |
| US20240238268A1 (en) * | 2021-09-09 | 2024-07-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Treatments and methods for treating alzheimer's disease |
| WO2023086026A2 (en) * | 2021-11-09 | 2023-05-19 | Agency For Science, Technology And Research | Method and composition for inhibiting telomerase activity |
| CN114259559B (zh) * | 2021-12-28 | 2024-03-19 | 天津科技大学 | 一种含有α-GalCer内源性佐剂的合成肿瘤疫苗 |
| WO2025233366A1 (en) * | 2024-05-07 | 2025-11-13 | Vib Vzw | Therapeutic and diagnostic applications of elongation of very long chain fatty acids protein 1 |
| EP4726041A1 (en) * | 2024-10-11 | 2026-04-15 | Instituto de Investigación Biomédica de Salamanca De la Fundación Instituto Ciencia de la Salud De Castilla y León | Med12 inhibitor, or pharmaceutical composition comprising thereof, for use in a method for the treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7049088B2 (en) * | 2001-06-05 | 2006-05-23 | Exelixis, Inc | PRMTs as modifiers of the p53 pathway and methods of use |
| WO2016044604A1 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
| MA54884A (fr) * | 2015-07-01 | 2022-01-12 | Immatics Biotechnologies Gmbh | Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome |
| ES2990061T3 (es) * | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| US20190343803A1 (en) * | 2016-12-01 | 2019-11-14 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| US11820822B2 (en) * | 2017-06-06 | 2023-11-21 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways |
| US12036222B2 (en) * | 2018-04-04 | 2024-07-16 | The Wistar Institut of Anatomy and Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor |
-
2021
- 2021-03-18 JP JP2022555911A patent/JP2023518396A/ja active Pending
- 2021-03-18 WO PCT/US2021/023023 patent/WO2021188828A1/en not_active Ceased
- 2021-03-18 US US17/910,864 patent/US20230201166A1/en active Pending
- 2021-03-18 EP EP21771184.5A patent/EP4121070A4/en active Pending
- 2021-03-18 CN CN202180035729.0A patent/CN115697356A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023518396A5 (https=) | ||
| Jin et al. | Recent progress and future perspectives of immunotherapy in advanced gastric cancer | |
| Yin et al. | Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1 | |
| Liu et al. | FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18. 2-targeted CAR-T against pancreatic cancer | |
| Kirtane et al. | Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead | |
| Luo et al. | Progress and prospect of immunotherapy for triple-negative breast cancer | |
| Han et al. | Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy | |
| Abbott et al. | To go or not to go? Biological logic gating engineered T cells | |
| Amatore et al. | Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy | |
| Wang et al. | Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications | |
| Guo et al. | B7-H3 in brain malignancies: immunology and immunotherapy | |
| Gauthier et al. | Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: clinical data to date, current limitations and perspectives | |
| Ishibashi et al. | Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1 | |
| Xiao et al. | Chimeric antigen receptor T-cell therapy in lung cancer: potential and challenges | |
| Xue et al. | Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy | |
| Guo et al. | Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment | |
| Kandra et al. | Utility and drawbacks of chimeric antigen receptor T cell (CAR-T) therapy in lung cancer | |
| Niu et al. | CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies | |
| Qiu et al. | Prospects of immunotherapy for triple-negative breast cancer | |
| Wang et al. | BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC | |
| Shadbad et al. | From melanoma development to RNA-modified dendritic cell vaccines: highlighting the lessons from the past | |
| Sanghera et al. | Immunotherapy–strategies for expanding its role in the treatment of all major tumor sites | |
| Chitadze et al. | Immune surveillance in glioblastoma: Role of the NKG2D system and novel cell‐based therapeutic approaches | |
| Pulido et al. | Hopes on immunotherapy targeting B7-H3 in neuroblastoma | |
| Klampatsa et al. | Current advances in CAR T cell therapy for malignant mesothelioma |